MDT

101.45

+0.95%↑

138.61

-0.74%↓

VEEV

225

+2.37%↑

HQY

86.43

+2.1%↑

NEOG

9.92

+0.61%↑

MDT

101.45

+0.95%↑

138.61

-0.74%↓

VEEV

225

+2.37%↑

HQY

86.43

+2.1%↑

NEOG

9.92

+0.61%↑

MDT

101.45

+0.95%↑

138.61

-0.74%↓

VEEV

225

+2.37%↑

HQY

86.43

+2.1%↑

NEOG

9.92

+0.61%↑

MDT

101.45

+0.95%↑

138.61

-0.74%↓

VEEV

225

+2.37%↑

HQY

86.43

+2.1%↑

NEOG

9.92

+0.61%↑

MDT

101.45

+0.95%↑

138.61

-0.74%↓

VEEV

225

+2.37%↑

HQY

86.43

+2.1%↑

NEOG

9.92

+0.61%↑

Home・Akcijų sąrašas・Immunocore Holdings PLC ADR

Immunocore Holdings PLC ADR

Atidarymo kaina

34.92 2.02

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

34.37

Max

35.82

Pagrindiniai rodikliai
By Trading Economics
Pajamos	10M -177K
Pardavimai	5.7M 104M
Pelno marža	-0.171
Darbuotojai	493
EBITDA	19M 4.1M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+93.7% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-02-25

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	54M 1.7B
Ankstesnė atidarymo kaina	32.9
Ankstesnė uždarymo kaina	34.92

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bearish Evidence

27.895 / 30.16 Palaikymas ir pasipriešinimas

Immunocore Holdings PLC ADR Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-01-21 23:49; UTC

Pagrindinės rinkos jėgos

Karman Space & Defense Shares Rise as 2026 Forecast Tops Analyst Estimates

2026-01-21 21:12; UTC

Pagrindinės rinkos jėgos

Automaker Stocks Rise After Trump Calls Off European Tariffs

2026-01-21 21:00; UTC

Įsigijimai, susijungimai, perėmimai

Deutsche Borse Group to Acquire Allfunds for $6.19 Billion

2026-01-21 20:29; UTC

Pagrindinės rinkos jėgos

Chip Makers Gain After Trump Calls Off European Tariffs

2026-01-21 20:04; UTC

Pagrindinės rinkos jėgos

Apparel, Footwear Stocks Rise After Trump Calls Off European Tariffs

2026-01-21 23:48; UTC

Rinkos pokalbiai

Nikkei May Rise as U.S.-Europe Tensions Ease -- Market Talk

2026-01-21 23:34; UTC

Rinkos pokalbiai

Gold Falls Amid Easing U.S.-Europe Tensions Over Greenland -- Market Talk

2026-01-21 22:39; UTC

Uždarbis

Schwab's Profit Jumps on Surge in Brokerage Activity -- 2nd Update

2026-01-21 21:50; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-01-21 21:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-01-21 21:35; UTC

Įsigijimai, susijungimai, perėmimai

Tesla Stock In Focus as Musk and Ryanair Chief Trade Insults. Should Investors Worry? -- Barrons.com

2026-01-21 21:19; UTC

Uždarbis

Charles Schwab Earnings Miss Estimates. The Stock Is Rising Anyway. -- Barrons.com

2026-01-21 20:45; UTC

Įsigijimai, susijungimai, perėmimai

Deutsche Borse Group to Acquire Allfunds for $6.19B

2026-01-21 20:36; UTC

Rinkos pokalbiai

U.S. Natural Gas Posts Back-to-Back Hefty Gains -- Market Talk

2026-01-21 20:31; UTC

Rinkos pokalbiai

Oil Settles Higher With Support From Heating Fuel -- Market Talk

2026-01-21 20:27; UTC

Įsigijimai, susijungimai, perėmimai

Deutsche Boerse Expects Combined Company Will Be Able to Achieve Annual Run Rate Pretax Cost Synergies of About EUR60M

2026-01-21 20:27; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-01-21 20:27; UTC

Rinkos pokalbiai

Was It a 'TACO' Event? -- Market Talk

2026-01-21 20:26; UTC

Įsigijimai, susijungimai, perėmimai

Deutsche Boerse Has Received Irrevocable Undertakings in Support of Acquisition in Respect of About 48.9% of Allfunds Issued Share Capital Excluding Treasury Shares

2026-01-21 20:23; UTC

Įsigijimai, susijungimai, perėmimai

Deutsche Boerse: Allfunds Stockholders to Receive EUR8.80/Shr, Including Cash, Stock and Permitted Dividend

2026-01-21 20:21; UTC

Įsigijimai, susijungimai, perėmimai

Deutsche Boerse: Agreement Values Allfunds at About EUR5.3B

2026-01-21 20:19; UTC

Įsigijimai, susijungimai, perėmimai

Deutsche Boerse Group Agrees to Buy Allfunds

2026-01-21 20:08; UTC

Uždarbis

Prologis Revenue Climbs as Warehouse Demand Rebounds -- Update

2026-01-21 20:03; UTC

Rinkos pokalbiai

Precious Metals Drop After Trump Posts About Greenland Deal -- Market Talk

2026-01-21 19:51; UTC

Rinkos pokalbiai

Treasury Markets React to Trump's Softer Tone About Greenland -- Market Talk

2026-01-21 19:43; UTC

Rinkos pokalbiai

U.S. Ethanol Production Expected to Slip -- Market Talk

2026-01-21 19:31; UTC

Rinkos pokalbiai

Gold Settles at Fresh All-Time High -- Market Talk

2026-01-21 19:24; UTC

Uždarbis

Johnson & Johnson Tops Earnings Estimates and Issues a Solid Outlook. The Stock Falls. -- Barrons.com

2026-01-21 19:10; UTC

Rinkos pokalbiai

Mexican Inflation Seen Picking Up in Early January -- Market Talk

2026-01-21 18:57; UTC

Rinkos pokalbiai

DAVOS: IBM CEO Krishna Says World Is More Volatile Now -- Market Talk

Akcijų palyginimas

Kainos pokytis

Immunocore Holdings PLC ADR Prognozė

Kainos tikslas

By TipRanks

93.7% į viršų

12 mėnesių prognozė

Vidutinis 64.56 USD 93.7%

Aukščiausias 100 USD

Žemiausias 37 USD

Remiantis 9 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Immunocore Holdings PLC ADR kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

9 ratings

Pirkti

Laikyti

Parduoti

Remiantis 9 analitikų, pateikusių Immunocore Holdings PLC ADR akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

27.895 / 30.16Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

There is one bearish event.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Immunocore Holdings PLC ADR

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.